In the metastatic melanoma setting, baseline levels of CD45RO8/CD8+ T cells and CD8+ effector memory predict response to immunotherapy, while the abundance of PD-1+CD56+ T cells inversely correlates with PFS and OS. Here, CD8A is linked to metastatic melanoma.